Skip to main content Accessibility help
×
Home

Functional improvement and correlations with symptomatic improvement in adults with attention deficit hyperactivity disorder receiving long-acting methylphenidate

  • J. K. Buitelaar (a1), M. Casas (a2), A. Philipsen (a3), J. J. S. Kooij (a4), J. A. Ramos-Quiroga (a2), J. Dejonckheere (a5), J. C. van Oene (a6) and B. Schäuble (a7)...

Abstract

Background

Data on the relationship between core symptoms and daily functioning in adults with attention deficit hyperactivity disorder (ADHD) are limited. Daily functioning was assessed as part of an open-label extension, and associations with symptom scores were evaluated.

Method

After a 5-week double-blind study with adults with ADHD receiving osmotic-controlled release oral delivery system (OROS) methylphenidate (MPH) 18, 36 or 72 mg/day, or placebo, participants were eligible for a 7-week open-label extension in which all patients received OROS MPH. Data for the Conners' Adult ADHD Rating Scale – Observer: Screening Version (CAARS-O:SV) (primary endpoint) have been presented previously. Secondary endpoints included the observer self-reported short version of the CAARS (CAARS-S:S) and the Clinical Global Impressions – Severity Scale (CGI-S). Daily functioning and quality of life were assessed using the Sheehan Disability Scale (SDS) and the Quality of Life Enjoyment and Satisfaction Questionnaire (Q-LES-Q) respectively. In post-hoc analyses, changes in CAARS-O:SV were evaluated in subgroups. Relationships between symptom and functional outcomes were evaluated in a multivariate regression analysis.

Results

A total of 370 patients entered the open-label extension. Significant improvements from baseline in CAARS-O:SV were similar regardless of sex, ADHD subtype, prior treatment or psychiatric co-morbidity. Significant improvements from double-blind baseline were also seen for the CAARS-S:S, CGI-S, SDS and Q-LES-Q. Improvements in the CAARS-O:SV Hyperactivity/Impulsivity subscale were associated with improvements in SDS total and subscale scores, and in the Q-LES-Q score at open-label endpoint. Improvements in CAARS-O:SV Inattention subscale and CGI-S scores were not significantly associated with functional changes.

Conclusions

Improvements in ADHD symptoms relating to hyperactivity and impulsivity in adults receiving OROS MPH are associated with improvements in daily functioning and quality of life.

  • View HTML
    • Send article to Kindle

      To send this article to your Kindle, first ensure no-reply@cambridge.org is added to your Approved Personal Document E-mail List under your Personal Document Settings on the Manage Your Content and Devices page of your Amazon account. Then enter the ‘name’ part of your Kindle email address below. Find out more about sending to your Kindle. Find out more about sending to your Kindle.

      Note you can select to send to either the @free.kindle.com or @kindle.com variations. ‘@free.kindle.com’ emails are free but can only be sent to your device when it is connected to wi-fi. ‘@kindle.com’ emails can be delivered even when you are not connected to wi-fi, but note that service fees apply.

      Find out more about the Kindle Personal Document Service.

      Functional improvement and correlations with symptomatic improvement in adults with attention deficit hyperactivity disorder receiving long-acting methylphenidate
      Available formats
      ×

      Send article to Dropbox

      To send this article to your Dropbox account, please select one or more formats and confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your <service> account. Find out more about sending content to Dropbox.

      Functional improvement and correlations with symptomatic improvement in adults with attention deficit hyperactivity disorder receiving long-acting methylphenidate
      Available formats
      ×

      Send article to Google Drive

      To send this article to your Google Drive account, please select one or more formats and confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your <service> account. Find out more about sending content to Google Drive.

      Functional improvement and correlations with symptomatic improvement in adults with attention deficit hyperactivity disorder receiving long-acting methylphenidate
      Available formats
      ×

Copyright

The online version of this article is published within an Open Access environment subject to the conditions of the Creative Commons Attribution-NonCommercial-ShareAlike licence . The written permission of Cambridge University Press must be obtained for commercial re-use.

Corresponding author

*Address for correspondence: Professor J. K. Buitelaar, Department of Cognitive Neuroscience (204), PO Box 9101, 6500 HB Nijmegen, The Netherlands. (Email: j.buitelaar@psy.umcn.nl)

References

Hide All
Adler, LA, Spencer, TJ, Levine, LR, Ramsey, JL, Tamura, R, Kelsey, D, Ball, SG, Allen, AJ, Biederman, J (2008 a). Functional outcomes in the treatment of adults with ADHD. Journal of Attention Disorders 11, 720727.
Adler, LA, Spencer, TJ, Williams, DW, Moore, RJ, Michelson, D (2008 b). Long-term, open-label safety and efficacy of atomoxetine in adults with ADHD: final report of a 4-year study. Journal of Attention Disorders 12, 248253.
Adler, LA, Sutton, VK, Moore, RJ, Dietrich, AP, Reimherr, FW, Sangal, RB, Saylor, KE, Secnik, K, Kelsey, DK, Allen, AJ (2006). Quality of life assessment in adult patients with attention-deficit/hyperactivity disorder treated with atomoxetine. Journal of Clinical Psychopharmacology 26, 648652.
Adler, LA, Zimmerman, B, Starr, HL, Silber, S, Palumbo, J, Orman, C, Spencer, T (2009). Efficacy and safety of OROS methylphenidate in adults with attention-deficit/hyperactivity disorder: a randomized, placebo-controlled, double-blind, parallel group, dose-escalation study. Journal of Clinical Psychopharmacology 29, 239247.
Arbuckle, R, Frye, MA, Brecher, M, Paulsson, B, Rajagopalan, K, Palmer, S, Degl'Innocenti, A (2009). The psychometric validation of the Sheehan Disability Scale (SDS) in patients with bipolar disorder. Psychiatry Research 165, 163174.
Aron, AR, Dowson, JH, Sahakian, BJ, Robbins, TW (2003). Methylphenidate improves response inhibition in adults with attention-deficit/hyperactivity disorder. Biological Psychiatry 54, 14651468.
Barkley, RA (1998). Attention-deficit hyperactivity disorder. Scientific American 279, 6671.
Barkley, RA, Murphy, KR, Fischer, M (2008). ADHD in Adults: What the Science Says. Guilford Press: New York.
Biederman, J, Mick, E, Surman, C, Doyle, R, Hammerness, P, Harpold, T, Dunkel, S, Dougherty, M, Aleardi, M, Spencer, T (2006). A randomized, placebo-controlled trial of OROS methylphenidate in adults with attention-deficit/hyperactivity disorder. Biological Psychiatry 59, 829835.
Boonstra, AM, Kooij, JJ, Oosterlaan, J, Sergeant, JA, Buitelaar, JK (2005 a). Does methylphenidate improve inhibition and other cognitive abilities in adults with childhood-onset ADHD? Journal of Clinical and Experimental Neuropsychology 27, 278298.
Boonstra, AM, Oosterlaan, J, Sergeant, JA, Buitelaar, JK (2005 b). Executive functioning in adult ADHD: a meta-analytic review. Psychological Medicine 35, 10971108.
Brown, TE, Landgraf, JM (2010). Improvements in executive function correlate with enhanced performance and functioning and health-related quality of life: evidence from 2 large, double-blind, randomized, placebo-controlled trials in ADHD. Postgraduate Medicine 122, 4251.
Buitelaar, JK, Ramos-Quiroga, JA, Casas, M, Kooij, JJ, Niemela, A, Konofal, E, Dejonckheere, J, Challis, BH, Medori, R (2009 a). Safety and tolerability of flexible dosages of prolonged-release OROS methylphenidate in adults with attention-deficit/hyperactivity disorder. Neuropsychiatric Disease and Treatment 5, 457466.
Buitelaar, JK, Wilens, TE, Zhang, S, Ning, Y, Feldman, PD (2009 b). Comparison of symptomatic versus functional changes in children and adolescents with ADHD during randomized, double-blind treatment with psychostimulants, atomoxetine, or placebo. Journal of Child Psychology and Psychiatry 50, 335342.
Endicott, J, Nee, J, Harrison, W, Blumenthal, R (1993). Quality of Life Enjoyment and Satisfaction Questionnaire: a new measure. Psychopharmacology Bulletin 29, 321326.
Fallu, A, Richard, C, Prinzo, R, Binder, C (2006). Does OROS-methylphenidate improve core symptoms and deficits in executive function? Results of an open-label trial in adults with attention deficit hyperactivity disorder. Current Medical Research and Opinion 22, 25572566.
Faraone, SV, Spencer, T, Aleardi, M, Pagano, C, Biederman, J (2004). Meta-analysis of the efficacy of methylphenidate for treating adult attention-deficit/hyperactivity disorder. Journal of Clinical Psychopharmacology 24, 2429.
Hambrick, JP, Turk, CL, Heimberg, RG, Schneier, FR, Liebowitz, MR (2004). Psychometric properties of disability measures among patients with social anxiety disorder. Journal of Anxiety Disorders 18, 825839.
Hervey, AS, Epstein, JN, Curry, JF (2004). Neuropsychology of adults with attention-deficit/hyperactivity disorder: a meta-analytic review. Neuropsychology 18, 485503.
Hudson, JI, Perahia, DG, Gilaberte, I, Wang, F, Watkin, JG, Detke, MJ (2007). Duloxetine in the treatment of major depressive disorder: an open-label study. BMC Psychiatry 7, 43.
Kessler, RC, Adler, L, Barkley, R, Biederman, J, Conners, CK, Demler, O, Faraone, SV, Greenhill, LL, Howes, MJ, Secnik, K, Spencer, T, Ustun, TB, Walters, EE, Zaslavky, AM (2006). The prevalence and correlates of adult ADHD in the United States: results from the National Comorbidity Survey Replication. American Journal of Psychiatry 163, 716723.
Leon, AC, Shear, MK, Portera, L, Klerman, GL (1992). Assessing impairment in patients with panic disorder: the Sheehan Disability Scale. Social Psychiatry and Psychiatric Epidemiology 27, 7882.
Lijffijt, M, Kenemans, JL, Verbaten, MN, van Engeland, H (2005). A meta-analytic review of stopping performance in attention-deficit/hyperactivity disorder: deficient inhibitory motor control? Journal of Abnormal Psychology 114, 216222.
Matza, LS, Johnston, JA, Faries, DE, Malley, KG, Brod, M (2007). Responsiveness of the Adult Attention-Deficit/Hyperactivity Disorder Quality of Life Scale (AAQoL). Quality of Life Research 16, 15111520.
Medori, R, Ramos-Quiroga, JA, Casas, M, Kooij, JJS, Niemelä, A, Trott, G-E, Lee, E, Buitelaar, JK (2008). A randomized, placebo-controlled trial of three fixed dosages of prolonged-release OROS methylphenidate in adults with attention-deficit/hyperactivity disorder. Biological Psychiatry 63, 981989.
Mick, E, Faraone, SV, Spencer, T, Zhang, HF, Biederman, J (2008). Assessing the validity of the Quality of Life Enjoyment and Satisfaction Questionnaire Short Form in adults with ADHD. Journal of Attention Disorders 11, 504509.
NIMH (1985). CGI: Clinical Global Impression Scale. Psychopharmacology Bulletin 21, 839843.
Pelham, WE, Gnagy, EM, Burrows-Maclean, L, Williams, A, Fabiano, GA, Morrisey, SM, Chronis, AM, Forehand, GL, Nguyen, CA, Hoffman, MT, Lock, TM, Fielbelkorn, K, Coles, EK, Panahon, CJ, Steiner, RL, Meichenbaum, DL, Onyango, AN, Morse, GD (2001). Once-a-day Concerta methylphenidate versus three-times-daily methylphenidate in laboratory and natural settings. Pediatrics 107, E105.
Peterson, K, McDonagh, MS, Fu, R (2008). Comparative benefits and harms of competing medications for adults with attention-deficit hyperactivity disorder: a systematic review and indirect comparison meta-analysis. Psychopharmacology (Berlin) 197, 111.
Rösler, M, Ginsberg, Y, Arngrim, T, Adamou, M, Niemelä, A, Dejonkheere, J, van Oene, J, Schäuble, B (2011). Correlation of symptomatic improvements with functional improvements and patient-reported outcomes in adults with attention-deficit/hyperactivity disorder treated with OROS methylphenidate. World Journal of Biological Psychiatry. Published online: 26 April 2011. doi:10.3109/15622975.2011.571283.
Roth, RM, Saykin, AJ (2004). Executive dysfunction in attention-deficit/hyperactivity disorder: cognitive and neuroimaging findings. Psychiatric Clinics of North America 27, 8396, ix.
Sheehan, DV, Harnett-Sheehan, K, Raj, BA (1996). The measurement of disability. International Clinical Psychopharmacology 11 (Suppl. 3), 8995.
Sheehan, KH, Sheehan, DV (2008). Assessing treatment effects in clinical trials with the discan metric of the Sheehan Disability Scale. International Clinical Psychopharmacology 23, 7083.
Spencer, TJ, Adler, LA, Weisler, RH, Youcha, SH (2008 a). Triple-bead mixed amphetamine salts (SPD465), a novel, enhanced extended-release amphetamine formulation for the treatment of adults with ADHD: a randomized, double-blind, multicenter, placebo-controlled study. Journal of Clinical Psychiatry 69, 14371448.
Spencer, TJ, Landgraf, JM, Adler, LA, Weisler, RH, Anderson, CS, Youcha, SH (2008 b). Attention-deficit/hyperactivity disorder-specific quality of life with triple-bead mixed amphetamine salts (SPD465) in adults: results of a randomized, double-blind, placebo-controlled study. Journal of Clinical Psychiatry 69, 17661775.
Swanson, J, Gupta, S, Lam, A, Shoulson, I, Lerner, M, Modi, N, Lindemulder, E, Wigal, S (2003). Development of a new once-a-day formulation of methylphenidate for the treatment of attention-deficit/hyperactivity disorder: proof-of-concept and proof-of-product studies. Archives of General Psychiatry 60, 204211.
Wolraich, ML, Greenhill, LL, Pelham, W, Swanson, J, Wilens, T, Palumbo, D, Atkins, M, McBurnett, K, Bukstein, O, August, G (2001). Randomized, controlled trial of OROS methylphenidate once a day in children with attention-deficit/hyperactivity disorder. Pediatrics 108, 883892.
Woods, SP, Lovejoy, DW, Ball, JD (2002). Neuropsychological characteristics of adults with ADHD: a comprehensive review of initial studies. Clinical Neuropsychology 16, 1234.

Keywords

Metrics

Full text views

Total number of HTML views: 0
Total number of PDF views: 0 *
Loading metrics...

Abstract views

Total abstract views: 0 *
Loading metrics...

* Views captured on Cambridge Core between <date>. This data will be updated every 24 hours.

Usage data cannot currently be displayed